文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

磁共振引导在线自适应立体定向体部放疗治疗晚期不可手术胰腺癌的前瞻性研究

Magnetic resonance-guided online adaptive stereotactic body radiotherapy for advanced inoperable pancreatic cancer: a prospective study.
PubMed 文献 · Radiat Oncol · 2025-12-18

该单中心前瞻性试验纳入34例不可切除胰腺导管腺癌患者,采用1.5T磁共振直线加速器行在线自适应SBRT(40–50 Gy/5次)联合系统治疗。中位随访12.3个月,6个月和1年局部控制率均为80.2%,97%患者3个月疼痛缓解,急性毒性以G1–2腹泻(18%)为主。结论认为短期控制令人鼓舞、毒性可控,需多中心长期验证。

要点

  • 6个月和1年局部控制率均为80.2%,中位远距离无进展生存9.7个月。
  • 97%患者放疗后3个月报告疼痛缓解。
  • 急性 probable 放疗相关毒性以G1–2腹泻(18%)为主,G2–3血小板减少18%。

核心结论

  • MRg-oART-SBRT在晚期不可切除胰腺癌中显示令人鼓舞的短期局部控制、可控毒性和生存信号。
  • 需更大规模多中心试验和更长随访验证长期疗效与临床实用性。

研究设计与样本

  • 单中心、开放标签、前瞻性试验,纳入≥18岁病理确诊胰腺导管腺癌患者,包括局部晚期、复发后和寡转移且多学科评估不可切除者。
  • ECOG 0–2患者无论是否接受过化疗均接受1.5T磁共振直线加速器在线自适应放疗,剂量40–50 Gy/5次。
  • 主要终点为6个月局部控制率;次要终点包括3个月疼痛缓解、90天内≥G3胃肠道毒性、6个月远距离无进展生存。

主要发现

  • 6个月和1年局部控制率均为80.2%。
  • 放疗后中位远距离无进展生存为9.7个月。
  • 放疗后3个月97%患者报告疼痛缓解。
  • 急性 probable 放疗相关毒性轻微,G1–2腹泻占18%。
  • 治疗相关不良反应最常见为血小板减少(G2–3:18%)和手足红斑感觉异常(G1–2:12%)。

临床怎么用

  • 对多学科评估不可切除的晚期胰腺癌患者,可考虑采用1.5T磁共振直线加速器行在线自适应SBRT(40–50 Gy/5次)联合系统治疗。
  • 治疗中需关注胃肠道毒性(如腹泻)及血液学毒性(如血小板减少)和手足皮肤反应。
  • 短期疼痛缓解率较高,可用于症状控制;长期疗效需进一步多中心验证。

局限性

  • 单中心、开放标签、样本量34例,随访时间较短(中位12.3个月)。
  • 试验为回顾性注册(2025年1月24日),注册号ChiCTR2500096492。
  • 需更大规模多中心试验和延长随访验证长期疗效与临床实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the local control, safety, and symptom relief of magnetic resonance-guided online adaptive stereotactic body radiation therapy (MRg-oART-SBRT) combined with systemic therapy in advanced unresectable pancreatic cancer. METHODS: This single-center, open-label, prospective trial enrolled ≥ 18-year-old patients with pathologically confirmed pancreatic ductal adenocarcinoma, including locally advanced, post-recurrent, and oligometastatic cases deemed unresectable via multidisciplinary evaluation. ECOG 0–2 patients with/without prior chemotherapy received 40–50 Gy/5 fractions via 1.5T MR-linear accelerator with daily online adaptive radiotherapy. Primary endpoint was 6-month local control rate; secondary endpoints included 3-month pain relief, ≥G3 gastrointestinal toxicity within 90 days, and 6-month distant progression-free survival. RESULTS: From November 2023 to December 2024, 34 patients completed MRg-oART-SBRT. With median follow-up of 12.3 months (IQR 9.0–14.4) after radiotherapy, the 6-month and 1-year local control rate were both 80.2%. Median distant progression-free survival was 9.7 months after radiotherapy. 97% reported pain relief at 3 months after radiotherapy. Acute probably radiation-related toxicity was mild (G1–2 diarrhea 18%). Thrombocytopenia (G2–3: 18%) and palmar-plantar erythrodysesthesia (G1–2: 12%) were most common treatment-related adverse reactions. CONCLUSION: MRg-oART-SBRT demonstrates encouraging short-term control, manageable toxicity, and survival signals in advanced pancreatic cancer. Larger multicenter trials with extended follow-up are warranted to validate long-term efficacy and clinical utility. TRIAL REGISTRATION: The study was registered on the Chinese Clinical Trial Registry, with the registration number ChiCTR2500096492.The retrospective registration date was January 24, 2025.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang C, Wang Z, Yu L, et al. Magnetic resonance-guided online adaptive stereotactic body radiotherapy for advanced inoperable pancreatic cancer: a prospective study. Radiat Oncol. 2025. PMID: 41413834. doi:10.1186/s13014-025-02776-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。